WO2004058055A3 - Method and system for disease detection using marker combinations - Google Patents

Method and system for disease detection using marker combinations Download PDF

Info

Publication number
WO2004058055A3
WO2004058055A3 PCT/US2003/041426 US0341426W WO2004058055A3 WO 2004058055 A3 WO2004058055 A3 WO 2004058055A3 US 0341426 W US0341426 W US 0341426W WO 2004058055 A3 WO2004058055 A3 WO 2004058055A3
Authority
WO
WIPO (PCT)
Prior art keywords
panel
objective function
markers
function
response
Prior art date
Application number
PCT/US2003/041426
Other languages
French (fr)
Other versions
WO2004058055A2 (en
Inventor
Joseph Michael Anderberg
Kenneth F Buechler
Paul H Mcpherson
Howard J Kirchick
Jeffrey R Dahlen
Original Assignee
Biosite Inc
Joseph Michael Anderberg
Kenneth F Buechler
Paul H Mcpherson
Howard J Kirchick
Jeffrey R Dahlen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/331,127 external-priority patent/US20040126767A1/en
Priority claimed from US10/410,572 external-priority patent/US20040121350A1/en
Application filed by Biosite Inc, Joseph Michael Anderberg, Kenneth F Buechler, Paul H Mcpherson, Howard J Kirchick, Jeffrey R Dahlen filed Critical Biosite Inc
Priority to AU2003300407A priority Critical patent/AU2003300407A1/en
Priority to EP03814398A priority patent/EP1588159A4/en
Priority to CA002511482A priority patent/CA2511482A1/en
Publication of WO2004058055A2 publication Critical patent/WO2004058055A2/en
Publication of WO2004058055A3 publication Critical patent/WO2004058055A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Medical Treatment And Welfare Office Work (AREA)

Abstract

The present invention relates to methods and system for the diagnosis diseases or conditions. In a particular aspect, a disclosed method for determining a panel includes calculating a panel response for each patient in a set of diseased patients and in a set of non-diseased patients. The panel response is a function of the value of each of a plurality of markers in a panel of markers. The method also includes calculating a value for an objective function. The objective function is indicative of the effectiveness of the panel. The steps of calculating a panel response for each patient and calculating a value for an objective function are iterated by varying at least one of the parameters relating to the panel response function and a sense of each marker to facilitate optimization of the objective function. The objective function may be a measure of an overlap of panel responses of diseased patients and panel responses of non-diseased patients. The contribution of each marker to the objective function may be determined, and the panel size may be reduced by removing the poorest markers. Thus, an optimum panel of markers and an optimal panel response function for the diagnosis of a disease or condition may be determined.
PCT/US2003/041426 2002-12-24 2003-12-23 Method and system for disease detection using marker combinations WO2004058055A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2003300407A AU2003300407A1 (en) 2002-12-24 2003-12-23 Method and system for disease detection using marker combinations
EP03814398A EP1588159A4 (en) 2002-12-24 2003-12-23 Method and system for disease detection using marker combinations
CA002511482A CA2511482A1 (en) 2002-12-24 2003-12-23 Method and system for disease detection using marker combinations

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US43639202P 2002-12-24 2002-12-24
US60/436,392 2002-12-24
US10/331,127 2002-12-27
US10/331,127 US20040126767A1 (en) 2002-12-27 2002-12-27 Method and system for disease detection using marker combinations
US10/410,572 2003-04-08
US10/410,572 US20040121350A1 (en) 2002-12-24 2003-04-08 System and method for identifying a panel of indicators

Publications (2)

Publication Number Publication Date
WO2004058055A2 WO2004058055A2 (en) 2004-07-15
WO2004058055A3 true WO2004058055A3 (en) 2005-04-07

Family

ID=32685981

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/041426 WO2004058055A2 (en) 2002-12-24 2003-12-23 Method and system for disease detection using marker combinations

Country Status (4)

Country Link
EP (1) EP1588159A4 (en)
AU (1) AU2003300407A1 (en)
CA (1) CA2511482A1 (en)
WO (1) WO2004058055A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
EP1692506A4 (en) * 2003-11-17 2008-01-09 Janssen Pharmaceutica Nv Modeling of systemic inflammatory response to infection
EP1628136A1 (en) * 2004-08-19 2006-02-22 B.R.A.H.M.S. Aktiengesellschaft Method of diagnosis of disease using copeptin
US20060292647A1 (en) * 2004-12-03 2006-12-28 Green Lawrence R Reflex supplemental testing - A rapid, efficient and highly accurate method to identify subjects with an infection, disease or other condition
WO2006073682A2 (en) 2004-12-09 2006-07-13 Meso Scale Technologies, Llc Diagnostic test
EP2095107B1 (en) 2006-11-14 2014-07-02 Alere San Diego, Inc. Methods for risk assignment
WO2008061149A2 (en) 2006-11-14 2008-05-22 Biosite Incorporated Methods and compositions for diagnosis and prognosis of renal artery stenosis
US8053198B2 (en) 2007-09-14 2011-11-08 Meso Scale Technologies, Llc Diagnostic methods
WO2010127057A2 (en) 2009-05-01 2010-11-04 Meso Scale Technologies, Llc. Biomarkers of therapeutic responsiveness
US20120058916A1 (en) 2009-05-13 2012-03-08 Meso Scale Technologies, Llc. Diagnostic methods for liver disorders
JP6251856B2 (en) 2011-09-29 2017-12-27 メソ スケール テクノロジーズ エルエルシー Biodosimetry panel and method
US20130164217A1 (en) 2011-12-21 2013-06-27 Meso Scale Technologies, Llc Method of diagnosing, preventing and/or treating dementia & related disorders
EP2684513A1 (en) 2012-07-13 2014-01-15 Universite D'angers Method for providing reliable non-invasive diagnostic tests
US20140127730A1 (en) * 2012-11-08 2014-05-08 Veterinary Diagnostics Institute, Inc. Method And System For Detecting Underlying Health Affections Using Biomarkers in Humans and Animals
US20140221325A1 (en) 2013-02-01 2014-08-07 Meso Scale Technologies, Llc Glomerulonephritis biomarkers
US20140221368A1 (en) 2013-02-01 2014-08-07 Meso Scale Technologies, Llc Biomarkers of therapeutic responsiveness
US20140309263A1 (en) 2013-02-01 2014-10-16 Meso Scale Technologies, Llc Biomarkers of therapeutic responsiveness
US20150038365A1 (en) 2013-08-01 2015-02-05 Meso Scale Technologies, Llc Lung cancer biomarkers
CA3093455A1 (en) 2018-03-08 2019-09-12 Meso Scale Technologies, Llc. Genetic marker and/or biomarkers for traumatic brain injury, and ultrasensitive assays for biomarkers of traumatic brain injury

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010023419A1 (en) * 1996-02-09 2001-09-20 Jerome Lapointe Method for selecting medical and biochemical diagnostic tests using neural network-related applications
WO2001088086A2 (en) * 2000-04-19 2001-11-22 Multiqtl Ltd. System and method for mapping of multiple trait complexes in multiple environments
US20020055186A1 (en) * 2000-09-19 2002-05-09 Oxford Glycosciences (Uk) Ltd. Detection of peptides
US20020095260A1 (en) * 2000-11-28 2002-07-18 Surromed, Inc. Methods for efficiently mining broad data sets for biological markers
US6485983B1 (en) * 1999-05-05 2002-11-26 Intec Science, Inc. System for electrochemical quantitative analysis of analytes within a solid phase and affinity chromatographic test strip

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6738001A (en) * 2000-04-28 2001-11-20 Bayer Aktiengesellschaft Assessment of liver fibrosis scoring with serum marker algorithms
JP4138486B2 (en) * 2001-01-24 2008-08-27 バイオウルフ テクノロジーズ エルエルスィー Classification of multiple features in data

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010023419A1 (en) * 1996-02-09 2001-09-20 Jerome Lapointe Method for selecting medical and biochemical diagnostic tests using neural network-related applications
US6485983B1 (en) * 1999-05-05 2002-11-26 Intec Science, Inc. System for electrochemical quantitative analysis of analytes within a solid phase and affinity chromatographic test strip
WO2001088086A2 (en) * 2000-04-19 2001-11-22 Multiqtl Ltd. System and method for mapping of multiple trait complexes in multiple environments
US20020055186A1 (en) * 2000-09-19 2002-05-09 Oxford Glycosciences (Uk) Ltd. Detection of peptides
US20020095260A1 (en) * 2000-11-28 2002-07-18 Surromed, Inc. Methods for efficiently mining broad data sets for biological markers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1588159A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes

Also Published As

Publication number Publication date
EP1588159A4 (en) 2008-03-12
EP1588159A2 (en) 2005-10-26
CA2511482A1 (en) 2004-07-15
AU2003300407A1 (en) 2004-07-22
WO2004058055A2 (en) 2004-07-15
AU2003300407A8 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
WO2004058055A3 (en) Method and system for disease detection using marker combinations
Bragança et al. On the brink of daily clinical application of objective gait analysis: What evidence do we have so far from studies using an induced lameness model?
Kao et al. Dynamic instability during post-stroke hemiparetic walking
WO2005023086A3 (en) Systems, methods, and computer program products for analysis of vessel attributes for diagnosis, disease staging, and surgical planning
Segal et al. Local dynamic stability in turning and straight-line gait
WO2003028571A3 (en) Method for identification and visualization of atrial tissue
Alsaaod et al. The cow pedogram—Analysis of gait cycle variables allows the detection of lameness and foot pathologies
Hegeman et al. Dual-tasking interferes with obstacle avoidance reactions in healthy seniors
EP1437674A3 (en) A method and a system for assisting a user in a medical self treatment
BR0315384A (en) Method and disposition to interpret head and eye activity of individuals
WO2007103977A3 (en) A physiogenomic method for predicting clinical outcomes of treatments in patients
WO2011080603A3 (en) Biofeedback for program guidance in pulmonary rehabilitation
WO2008086434A3 (en) Depositing radiation in heart muscle under ultrasound guidance
EP0945060A3 (en) Method and system for monitoring animals
WO2006002396A3 (en) Radiation therapy of the lungs using leadless markers
WO2005108999A3 (en) Diagnostic and therapeutic use of kcnj6 for alzheimer’s disease
WO2005098429A3 (en) System and method for real-time diagnosis, treatment, and therapeutic drug monitoring
WO2008024137A3 (en) Novel method and apparatus for determining optimal neuromuscular detection sites, novel diagnostic biosensor array formed in accordance with the same, and novel method for testing a patient using the novel diagnostic biosensor array
Matson et al. How does balance during functional tasks change across older adulthood?
WO2006059252A3 (en) Methods and fluorinated compositions for treating amyloid-related diseases
JP2008264114A (en) Diagnostic program of moving motion state, diagnostic apparatus of moving motion state, and diagnostic method of moving motion state
Pantall et al. Stance and swing phase detection during level and slope walking in the cat: effects of slope, injury, subject and kinematic detection method
CA2575405A1 (en) Method for diagnosing liver fibrosis
WO2000070340A3 (en) Materials and methods relating to disease diagnosis
WO2006110768A3 (en) System, method and software arrangement for analyzing and correlating molecular profiles associated with anatomical structures

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2511482

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003814398

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003814398

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP